Skip to main content
SpringerLink
Log in

Common clinical indications for anticoagulation

  • Chapter
Handbook of Oral Anticoagulation

  • 568 Accesses

Abstract

As discussed in Chapter 1, an anticoagulant is a substance that possesses the properties to limit clot formation and therefore can be used therapeutically to prevent or treat thrombotic disorders. In this chapter we discuss the common clinical conditions in which anticoagulation should be considered and the evidence available to justify use of an appropriate antithrombotic therapy in these clinical settings.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Heit JA, Melton LJ 3rd, Lohse CM, et al. Incidence of venous thromboembolism in hospitalized patients vs community residents. Mayo Clin Proc 2001;76:1102–10.

    Article  PubMed  CAS  Google Scholar 

  2. Fowkes FJ, Price JF, Fowkes FG. Incidence of diagnosed deep vein thrombosis in the general population: systematic review. Eur J Vasc Endovasc Surg 2003;25:1–5.

    Article  PubMed  CAS  Google Scholar 

  3. Hansson PO, Sörbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 2000;160:769–74.

    Article  PubMed  CAS  Google Scholar 

  4. Morrell MT, Dunnill MS. The post-mortem incidence of pulmonary embolism in a hospital population. Br J Surg 1968;55:347–52.

    Article  PubMed  CAS  Google Scholar 

  5. Heit JA, Silverstein MD, Mohr DN, et al. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 1999;159:445–53.

    Article  PubMed  CAS  Google Scholar 

  6. Dentali F, Douketis JD, Gianni M, et al. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med 2007;146:278–88.

    Article  PubMed  Google Scholar 

  7. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988;318:1162–73.

    Article  PubMed  CAS  Google Scholar 

  8. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients: results of meta-analysis. Ann Surg 1988;208:227–40.

    Article  PubMed  CAS  Google Scholar 

  9. Mismetti P, Laporte S, Darmon JY, et al. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 2001;88, 913–30.

    Article  PubMed  CAS  Google Scholar 

  10. Wein L, Wein S, Haas SJ, et al. Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: a meta-analysis of randomized controlled trials. Arch Intern Med 2007;167:1476–86.

    Article  PubMed  CAS  Google Scholar 

  11. Deitelzweig SB, Becker R, Lin J, Benner J. Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venous thromboembolism. Thromb Haemost 2008;100:810–20.

    PubMed  CAS  Google Scholar 

  12. Nurmohamed MT, Rosendaal FR, Büller HR, et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992;340:152–6.

    Article  PubMed  CAS  Google Scholar 

  13. Hull RD, Raskob GE, Pineo G, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993;329:1370–6.

    Article  PubMed  CAS  Google Scholar 

  14. Francis CW, Pellegrini VD Jr, Totterman S, et al. Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin. J Bone Joint Surg Am 1997;79:1365–72.

    PubMed  CAS  Google Scholar 

  15. Agnelli, G, Bergqvist, D, Cohen, A, et al. Randomized double-blind study to compare the efficacy and safety of postoperative fondaparinux (Arixtra) and preoperative dalteparin in the prevention of venous thromboembolism after high-risk abdominal surgery: the PEGASUS Study [abstract]. Blood 2003;102, 15a.

    Google Scholar 

  16. Francis CW, Berkowitz SD, Comp PC, et al.; EXULT A Study Group. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003;349:1703–12.

    Article  PubMed  CAS  Google Scholar 

  17. Colwell CW Jr, Berkowitz SD, Lieberman JR, et al.; EXULT B Study Group. Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. J Bone Joint Surg Am 2005;87:2169–77.

    Article  PubMed  Google Scholar 

  18. Geerts WH, Bergqvist D, Pineo GF, et al. American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:381–453S.

    Article  Google Scholar 

  19. Howard PA. Dalteparin: a low-molecular-weight heparin. Ann Pharmacother 1997;31:92–203.

    Google Scholar 

  20. Dolovich LR, Ginsberg JS, Douketis JD, et al. A meta-analysis comparing low-molecularweight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000;160:181–8.

    Article  PubMed  CAS  Google Scholar 

  21. Green D, Hirsh J, Heit J, et al. Low molecular weight heparin: a critical analysis of clinical trials. Pharmacol Rev 1994;46:89–109.

    PubMed  CAS  Google Scholar 

  22. Raschke R, Hirsh J, Guidry JR. Suboptimal monitoring and dosing of unfractionated heparin in comparative studies with low-molecular-weight heparin. Ann Intern Med 2003;138:720–3.

    Article  PubMed  CAS  Google Scholar 

  23. Büller HR, Davidson BL, Decousus H, et al.; Matisse Investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004;140:867–73.

    Article  PubMed  Google Scholar 

  24. Vinson DR, Berman DA. Outpatient treatment of deep venous thrombosis: a clinical care pathway managed by the emergency department. Ann Emerg Med 2001;37:251–8.

    Article  PubMed  CAS  Google Scholar 

  25. Smith BJ, Weekley JS, Pilotto L, et al. Cost comparison of at-home treatment of deep venous thrombosis with low molecular weight heparin to inpatient treatment with unfractionated heparin. Intern Med J 2002;32:29–34.

    Article  PubMed  CAS  Google Scholar 

  26. Segal JB, Streiff MB, Hofmann LV, et al. Management of venous thromboembolism: a systematic review for a practice guideline. Ann Intern Med 2007;146:211–22.

    Article  PubMed  Google Scholar 

  27. Das SK, Cohen AT, Edmondson RA, et al. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World J Surg 1996;20:521–6.

    Article  PubMed  CAS  Google Scholar 

  28. Lee AY, Levine MN, Baker RI, et al.; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146–53.

    Article  PubMed  CAS  Google Scholar 

  29. Agnelli G, Prandoni P, Santamaria MG, et al.; Warfarin Optimal Duration Italian Trial Investigators. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med 2001;345:165–9.

    Article  PubMed  CAS  Google Scholar 

  30. Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med 1995;332:1661–5.

    Article  PubMed  CAS  Google Scholar 

  31. Schulman S, Granqvist S, Holmström M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med 1997;336:393–8.

    Article  PubMed  CAS  Google Scholar 

  32. Kearon C, Ginsberg JS, Kovacs MJ, et al.; Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003;349:631–9.

    Article  PubMed  CAS  Google Scholar 

  33. Ridker PM, Goldhaber SZ, Danielson E, et al.; PREVENT Investigators. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003;348:1425–34.

    Article  PubMed  CAS  Google Scholar 

  34. van Gogh Investigators, Buller HR, Cohen AT, et al. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007;357:1094–104.

    Article  Google Scholar 

  35. Elsharawy M, Elzayat E. Early results of thrombolysis vs anticoagulation in iliofemoral venous thrombosis. A randomised clinical trial. Eur J Vasc Endovasc Surg 2002;24:209–14.

    Article  PubMed  CAS  Google Scholar 

  36. Comerota AJ, Throm RC, Mathias SD, et al. Catheter-directed thrombolysis for iliofemoral deep venous thrombosis improves health-related quality of life. J Vasc Surg 2000;32:130–7.

    Article  PubMed  CAS  Google Scholar 

  37. Razavi MK, Wong H, Kee ST, et al. Initial clinical results of tenecteplase (TNK) in catheterdirected thrombolytic therapy. J Endovasc Ther 2002;9:593–8.

    Article  PubMed  Google Scholar 

  38. Plate G, Einarsson E, Ohlin P, et al. Thrombectomy with temporary arteriovenous fistula: the treatment of choice in acute iliofemoral venous thrombosis. J Vasc Surg 1984;1:867–76.

    PubMed  CAS  Google Scholar 

  39. Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d’Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 1998;338:409–15.

    Article  PubMed  CAS  Google Scholar 

  40. White RH, Zhou H, Kim J, Romano PS. A population-based study of the effectiveness of inferior vena cava filter use among patients with venous thromboembolism. Arch Intern Med 2000;160:2033–41.

    Article  PubMed  CAS  Google Scholar 

  41. Wan S, Quinlan DJ, Agnelli G, Eikelboom JW. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation 2004;110:744–9.

    Google Scholar 

  42. Büller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:401–28S.

    Article  Google Scholar 

  43. Kearon C, Kahn SR, Agnelli G, et al.; American College of Chest Physicians. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:454–545S.

    Article  Google Scholar 

  44. Otten HM, Prins MH. Venous thromboembolism and occult malignancy. Thromb Res 2001;102:V187–94.

    Article  PubMed  CAS  Google Scholar 

  45. Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham heart study. Circulation 2004;110:1042–46.

    Article  PubMed  Google Scholar 

  46. Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006;27:949–53.

    Article  PubMed  Google Scholar 

  47. Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001;86:516–21.

    Article  PubMed  CAS  Google Scholar 

  48. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006;114:119–25.

    Article  PubMed  Google Scholar 

  49. Lip GY, Boss CJ. Antithrombotic treatment in atrial fibrillation. Heart 2006;92:155–61.

    Article  PubMed  CAS  Google Scholar 

  50. Fuster V, Rydén LE, Cannom DS, et al.; Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology. ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation. J Am Coll Cardiol 2006;48:e149–246.

    Article  Google Scholar 

  51. Klein AL, Jasper SE, Katz WE, et al.; ACUTE II Steering and Publications Committee for the ACUTE II Investigators. The use of enoxaparin compared with unfractionated heparin for short-term antithrombotic therapy in atrial fibrillation patients undergoing transoesophageal echocardiography-guided cardioversion: assessment of Cardioversion Using Transoesophageal Echocardiography (ACUTE) II randomized multicentre study. Eur Heart J 2006;27:2858–65.

    Article  PubMed  CAS  Google Scholar 

  52. Wu LA, Chandrasekaran K, Friedman PA, et al. Safety of expedited anticoagulation in patients undergoing transesophageal echocardiographic-guided cardioversion. Am J Med 2006;119:142–6.

    Article  PubMed  Google Scholar 

  53. Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 2007;69:546–54.

    Article  Google Scholar 

  54. Hart RG, Pearce LA, Agullar MI. Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation: a meta-analysis. Ann Intern Med 2007;146:857–67.

    Article  PubMed  Google Scholar 

  55. Lip GY, Edwards SJ. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systemic review and meta-analysis. Thromb Res 2006;118:321–33.

    Article  PubMed  CAS  Google Scholar 

  56. Stroke Prevention in Atrial Fibrillation investigators. A differential effect of aspirin in prevention of stroke on atrial fibrillation. J Stroke Cerebrovasc Dis 1993;3:181–8.

    Google Scholar 

  57. ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE W). Lancet 2006;367:1903–12.

    Article  Google Scholar 

  58. Mant J, Hobbs FD, Fletcher K, et al.; BAFTA investigators; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007;370:493–503.

    Article  PubMed  CAS  Google Scholar 

  59. Stein PD, Alpert JS, Bussey HI, et al. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest. 2001;119:220–7S.

    Article  Google Scholar 

  60. American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Society of Cardiovascular Anesthesiologists; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons, Bonow RO, Carabello BA, Kanu C, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 2006;114:e84–231.

    Article  PubMed  Google Scholar 

  61. Vaitkus PT. Left ventricular mural thrombus and the risk of embolic stroke after acute myocardial infarction. J Cardiovasc Risk 1995;2:103–6.

    Article  PubMed  CAS  Google Scholar 

  62. Loh E, Sutton MS, Wun CC, et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997;336:251–7.

    Article  PubMed  CAS  Google Scholar 

  63. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction — Executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 2004;110:588–636.

    Article  PubMed  Google Scholar 

  64. Tangelder MJ, Frison L, Weaver D, et al. Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial. Am Heart J 2008;155:382–7.

    Article  PubMed  CAS  Google Scholar 

  65. Coumadin Aspirin Refarction Study (CARS) Investigators. Randomised double-blind trial of fixed low dose warfarin with aspirin after myocardial infarction. Lancet 1997;350:389–96.

    Article  Google Scholar 

  66. Fiore L, Ezekowitz MD, Brophy MT, et al. Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. Circulation 2002;105:557–63.

    Article  PubMed  CAS  Google Scholar 

  67. Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin or both after myocardial infarction. N Engl J Med 2002;347:969–74.

    Article  PubMed  CAS  Google Scholar 

  68. Van Es RF, Jonker JJC, Verheugt FWA, et al. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study). Lancet 2002;360:109–13.

    Article  PubMed  Google Scholar 

  69. Lip GYH, Karpha M. Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing percutaneous coronary intervention: the need for consensus and a management guideline. Chest 2006;130:1823–7.

    Article  PubMed  CAS  Google Scholar 

  70. Lip GY, Gibbs CR. Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm: a Cochrane systematic review. Q J Med 2002;95:461–8.

    Article  CAS  Google Scholar 

  71. Lip GYH, Gibbs CR. Anticoagulation for heart failure in sinus rhythm: a Cochrane systemic review. Q J Med 2002;95:451–9.

    Article  CAS  Google Scholar 

  72. Cleland JG, Findlay I, Jafri S, et al. The Warfarin/Aspirin Study in Heart Failure (WASH): a randomised trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 2004;148:157–64.

    Article  PubMed  CAS  Google Scholar 

  73. Massie BM, Krol WF, Ammon SE, et al. The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics. J Card Fail 2004;10:101–12.

    Article  PubMed  CAS  Google Scholar 

  74. Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF). www.clinicaltrials.gov, Identifier: NCT00041938

  75. Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989;i:175–9.

    Article  Google Scholar 

  76. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323:1505–11.

    Article  Google Scholar 

  77. Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991;18:349–55.

    Article  PubMed  CAS  Google Scholar 

  78. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993;342:1255–62.

    Google Scholar 

  79. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991;84:527–39.

    Google Scholar 

  80. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992;327:1406–12.

    Article  PubMed  CAS  Google Scholar 

  81. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1–13.

    Article  PubMed  CAS  Google Scholar 

  82. Benavente O, Hart R, Koudstaal P, et al. Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2000;(2):CD001925.

    Google Scholar 

  83. Japan Atrial Fibrillation Stroke Trial Group. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stoke Trial. Stroke 2006;37:447–51.

    Article  Google Scholar 

  84. Posada IS, Barriales V. Alternate-day dosing of aspirin in atrial fibrillation. LASAF Pilot Study Group. Am Heart J 1999;138:137–43.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Suresh Krishnamoorthy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chee W Khoo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eduard Shantsila
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gregory Y H Lip
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Healthcare Ltd, a part of Springer Science+Business Media

About this chapter

Cite this chapter

Krishnamoorthy, S., Khoo, C.W., Shantsila, E., Lip, G.Y.H. (2010). Common clinical indications for anticoagulation. In: Handbook of Oral Anticoagulation. Springer Healthcare, Tarporley. https://doi.org/10.1007/978-1-908517-08-1_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-908517-08-1_2

  • Publisher Name: Springer Healthcare, Tarporley

  • Print ISBN: 978-1-85873-452-1

  • Online ISBN: 978-1-908517-08-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation